TMEM59L

Across TCGA pan-cancer cohorts, TMEM59L Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM59L data layer compared with 26 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher TMEM59L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM59L expression acts as an unfavorable survival marker.

SARC, UCEC, and STAD are the cancer types where TMEM59L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.162	0.767	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM59L–SARC (OS)

Open the SARC breakdown →